Latest Revenue Growth News

CAR Group Limited has reported solid full-year FY25 results with revenue surpassing AUD 1.18 billion and adjusted NPAT rising to AUD 377 million, underpinned by global marketplace strength and strategic innovation. The company projects continued double-digit growth in FY26, driven by technology investments and market expansion.

CAR Group Limited has reported strong FY25 financial results with double-digit revenue and earnings growth across all key markets, while preparing for a leadership change. The company’s optimistic FY26 outlook underscores confidence in sustained expansion driven by innovation and market leadership.

CAR Group Limited reported a strong FY25 with revenue up 8% to $1.18 billion and net profit after tax rising 12% to $293 million, while announcing a leadership transition as CEO Cameron McIntyre steps down.

ResMed Inc. reported a robust 10% increase in revenue to $5.15 billion for fiscal 2025, driven by strong demand in sleep and breathing health devices and residential care software. The company also expanded its diagnostic capabilities with the acquisition of VirtuOx, positioning itself for further growth in home-based health solutions.

Avita Medical reported an 18% revenue increase and a 30% reduction in net loss for the first half of 2025, signaling progress as it scales commercial operations and targets profitability by 2026.

AVITA Medical reported a 21% revenue increase in Q2 2025 driven by expanded sales and new product launches, yet continues to face net losses and liquidity challenges requiring loan covenant waivers.

Wrkr Limited is raising approximately A$15 million through an institutional placement to accelerate growth amid upcoming Payday Super reforms and market opportunities.

Memphasys Limited pivots from development to commercial execution with its flagship IVF product Felix, targeting global markets through direct sales and recurring revenue streams.

COSOL Limited reports FY25 revenue and EBITDA below guidance due to timing delays but highlights a 17% rise in operating cash flow and maintains optimistic FY26 growth forecasts.

Nick Scali Limited reported a solid FY25 underlying profit of $62 million, driven by strong ANZ sales and online growth, while UK operations continue to struggle amid store refurbishments and brand repositioning.

AVITA Medical’s Q2 2025 update reveals a temporary setback in RECELL demand due to Medicare reimbursement delays, offset by strong revenue growth and promising clinical data. The company anticipates recovery and renewed growth in the second half of the year.

Nick Scali Limited reported a 5.8% revenue increase to $495.3 million in FY25, driven by its UK acquisition, but statutory net profit fell 28.4% amid integration and freight disruption costs. The company declared a fully franked final dividend of 33 cents per share.